PLOS ONE · 5 authors, 6 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
A retrospective cohort study of 55 patients with BMI ≥ 42.5 kg/m² who underwent one-anastomosis gastric bypass found that a preoperative orlistat-based regimen produced modest weight loss in 64% of patients and was associated with shorter operative time, but did not result in greater weight loss at 24 months postoperatively.
This retrospective cohort study reviewed 55 patients aged 20–65 with BMI ≥ 42.5 kg/m² who underwent primary one-anastomosis gastric bypass at a single center from 2014 to 2020. Eligible patients followed a 4–6 week preoperative program centered on orlistat (120 mg three times daily for 10–14 days) combined with dietary and lifestyle modification. Thirty-five patients (64%) achieved weight loss (Group 1; median 2.0 kg lost) while 20 gained weight (Group 2; median 2.9 kg gained). Weight loss did not differ between groups at 24 months. Study limitations include retrospective design, potential selection bias, and reliance on self-reported compliance.
